Reviva pharmaceuticals announces update on recover, a pivotal phase 3 global study evaluating brilaroxazine for the treatment of schizophrenia

Cupertino, calif., may 03, 2022 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph) (“reviva” or the “company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), cardiovascular, metabolic, and inflammatory diseases, today announced that the recover study is progressing well and all sites in the united states (u.s.) have been initiated. global sites in europe and india remain on track to initiate in mid-2022.
RVPH Ratings Summary
RVPH Quant Ranking